TITLE

Good Science And The Marketplace For Drugs: A Conversation With Jean-Pierre Garnier

AUTHOR(S)
Iglehart, John K.
PUB. DATE
July 2003
SOURCE
Health Affairs;Jul/Aug2003, Vol. 22 Issue 4, p119
SOURCE TYPE
Academic Journal
DOC. TYPE
Interview
ABSTRACT
Interviews Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline. Expansion of the scope of Medicare's prescription drug benefits; GlaxoSmithKline's drug research and development activities; Challenges posed by the generic market; Future of drug development.
ACCESSION #
10254251

 

Related Articles

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune International (Europe);3/21/2005, Vol. 151 Issue 5, p20 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune;3/21/2005, Vol. 151 Issue 6, p38 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • SPEAKING OUT: JEAN-PIERRE GARNIER.  // Management Today;Mar2006, p14 

    The article presents the views of Jean-Pierre Garnier, CEO, GlaxoSmithKline (GSK), at the CBI Interactive Conference. Under his stewardship, GSK has streaked ahead with a pipeline of new drugs twice the size of its nearest competitor's. Garnier says innovation is all about people, but truly...

  • GKS: A Pipeline to Brag About? Houlton, Sarah // Pharmaceutical Executive;Jan2004, Vol. 24 Issue 1, p22 

    Reports the claim by Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline PLC (GSK), that of the 147 products GSK has in clinical trials, at least 20 have blockbuster potential. Drop in the company's price share; Potential of the company's therapeutic areas; Company's reorganization.

  • Fat-cat salaries are the best way to get the cream. Pitcher, George // Marketing Week;5/29/2003, Vol. 26 Issue 22, p27 

    Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay...

  • GSK Names New Chairman.  // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p174 

    The article announces the appointment of Moncef Slaoui as chairman of research and development at GlaxoSmithKline effective June 1, 2006. Slaoui will report to Chief Executive Officer Jean-Pierre Garnier. Slaoui succeeds Tadataka Yamada who will retire from the company to become executive...

  • GSK makes strides in R&D.  // European Chemical News;12/8/2003, Vol. 79 Issue 2080, p28 

    Reports on the research and development (R&D) achievements of GlaxoSmithKline (GSK) presented by chief executive officer Jean-Pierre Garnier to investors in December 2003. Number of projects in clinical development; Number of chemical entities developed by GSK; R&D innovation launched by the...

  • GSK Revisits Exec Pay. Houlton, Sarah // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28 

    Reports on the plan created by GlaxoSmithKline PLC for compensating senior executives to replace a plan rejected by stockholders in Great Britain. Problem of investors with the original proposal; Changes made to the contracts of other executive directors; Salary and bonus package received by...

  • Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

    Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics